Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Chondroitin sulfate-iron colloid** is an intravenous colloidal ferric-iron preparation in which iron colloid is stabilized by chondroitin sulfate. It was marketed in Japan as **Blutal** for treatment of iron deficiency anemia, including use as parenteral iron support in hemodialysis-associated anemia. The colloid delivers iron for utilization in hemoglobin synthesis and replenishment of iron stores. Its paramagnetic ferric iron and preferential uptake by the hepatic reticuloendothelial system, including Kupffer cells, also enabled investigational use as an MRI contrast agent for liver lesion and hepatocellular carcinoma imaging. Blutal was subject to a Japanese Class II recall in July 2006 following increased reports of drug eruptions after a change in the chondroitin sulfate raw-material source.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chondroitin sulfate-iron colloid.